Moderna (MRNA) Long-Term Deferred Tax (2021 - 2024)

Moderna (MRNA) has 4 years of Long-Term Deferred Tax data on file, last reported at $81.0 million in Q3 2024.

• Long-Term Deferred Tax for Q3 2024 came in at $81.0 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2024 was $81.0 million (changed N/A YoY), and the FY2023 annual result was $81.0 million, down 91.75% from the prior year.
• Long-Term Deferred Tax held at $81.0 million in Q3 2024 per MRNA's latest filing, from $81.0 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $1.5 billion in Q2 2023 and troughed at $50.0 million in Q1 2021.
• A 4-year average of $485.5 million and a median of $203.5 million in 2021 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2022 and 2024: Long-Term Deferred Tax jumped 1089.39% in 2022, then sank 94.53% in 2024.
• A 4-year view of Long-Term Deferred Tax shows it stood at $326.0 million in 2021, then jumped by 201.23% to $982.0 million in 2022, then sank by 91.75% to $81.0 million in 2023, then changed by 0.0% to $81.0 million in 2024.
• Business Quant data shows MRNA's Long-Term Deferred Tax at $81.0 million in Q3 2024, $81.0 million in Q2 2024, and $81.0 million in Q1 2024.